Synthesis, Characterization, Crystal Structure, and DFT Study of a New Square Planar Cu(II) Complex Containing Bulky Adamantane Ligand

Monther A. Khanfar *, Areej M. Jaber, Murad A. AlDamen and Raed A. Al-Qawasmeh

Department of Chemistry, Faculty of Science, the University of Jordan, Amman 11942, Jordan; areejmajed@ju.edu.jo (A.M.J.); maldamen@ju.edu.jo (M.A.A.); r.alqawasmeh@ju.edu.jo (R.A.A.)
* Correspondence: m.khanfar@ju.edu.jo; Tel.: +962-6535-5000

Received: 26 February 2018; Accepted: 13 March 2018; Published: 20 March 2018

Abstract: A copper complex with square planar geometry, [(L)CuBr$_2$] (1), (L = N′-(furan-2-ylmethylene)adamantane-1-carbohydrazide) has been synthesized and characterized by Fourier transfer infrared (FTIR) spectroscopy, elemental analysis, mass spectrometry, and single crystal X-ray diffraction. The crystal of 1 is solved as monoclinic, space group P2$_1$/m with unit cell parameters: $a = 10.8030(8)$, $b = 6.6115(8)$, $c = 12.1264(12)$ Å, $\beta = 101.124(8)$°, $V = 849.84(15)$ Å$^3$, $Z = 2$, and $R_1 = 0.0751$ with $wR_2 = 0.1581$ (I > 2σ). The structure of 1 shows intramolecular hydrogen bonding between the N–H and the furan oxygen which stabilizes the configuration of the complex. Furthermore, inside the lattice there are other weak interactions between bromo ligands and the ligand L. DFT calculations were performed to study the stability of this geometry.

Keywords: 2-furyl adamantane hydrazone; hydrazone complexes; square planar copper(II) complex; DFT

1. Introduction

Hydrazones constitute an important class of compounds and have been extensively studied due to their rapid access, availability, and diversity. Incorporation of a carbonyl group to hydrazones forms the acrylhydrazones, which in turn have an additional ligating site. Compounds of this type were accessed due to their biological significance as, for example, antifungal [1,2] antimicrobial [3–9], and anticancer [10–12] agents. Furthermore, an adamantane moiety has been known to enhance biological significance when anchored on certain scaffolds [13–18]. On the other hand, numerous instances of metabolism and transportation of metal ions and complexes have been established, as well as the importance of introducing adamantane on metal ion-containing hydrazones, yet less attention was devoted to such compounds [19–22]. Copper is considered to be an essential trace element in biological systems [23–25]. The importance of the coordination of copper with ligands containing adamantane [26] has also been investigated. Recently, copper complexes as a substitute of cisplatin complexes as anticancer agents have been reviewed [27,28]. Among the variety of coordination numbers and geometry that copper could deliver, the square planar geometry would be most attractive. Nevertheless, incorporation of metal ions with biologically active ligands may not enhance the activity. This may be attributed to structural changes that the metal ion could make in the structure of the organic ligand [29]. It is still a challenging task to collect active functional groups in a compound, especially for drugs [29]. Quite recently, we reported the synthesis of new adamantane-containing hydrazone compounds, where furan was one of the arms within the hydrazine-adamantyl compounds [30,31]. Herein, we report on the synthesis and study of the structural properties of copper(II) complex of N′-(furan-2-ylmethylene)adamantane-1-carbohydrazide which may possess a potent anticancer activity.
Interestingly, the synthesized complex showed a symmetrical square planar geometry as indicated by X-ray single crystal crystallography.

2. Results and Discussion

2.1. Preparation and Characterization of the Copper(II) Complex

The ligand was prepared as described [30,31] by refluxing an equimolar mixture of admantane-1-carboxylic acid hydrazine with furane-2-caebaldehyde in ethanol to produce the desired ligand, which was identified with an authentic sample [30,31]. The reaction of L with copper(II) bromide (CuBr₂) under the solvothermal condition results in the formation of Cu(II) complex (Scheme 1). High resolution mass spectrometry (HRMS) of the complex gave the corresponding exact molecular mass. IR bands \( \nu \) (cm\(^{-1}\)) assigned to stretching (C=O) at 1593 (s) cm\(^{-1}\) and (C=N) at 1526 (s) cm\(^{-1}\) clearly shows the weakness of the carbonyl group as well as C=N upon complexation.

![Scheme 1](image)

Scheme 1. Synthesis of copper(II) complex 1.

2.2. Description of the Crystal Structure

Single X-ray crystallography measurements show that \([\text{C}_{16}\text{H}_{20}\text{Br}_{2}\text{CuN}_{2}\text{O}_{2}] \) (1) crystallizes in the monoclinic system, with space group \( P2_1/m \) and crystallographic data listed in Table 1. The asymmetric unit of 1 (Figure 1) contains one molecular unit.

| Crystal System | Monoclinic |
|----------------|------------|
| \( T/K \)      | 293(2)     |
| Space group    | \( P2_1/m \) |
| \( a/\text{Å} \) | 10.8030(8) |
| \( b/\text{Å} \) | 6.6115(8)  |
| \( c/\text{Å} \) | 12.1264(12) |
| \( \beta/\degree \) | 101.124(8) |
| Volume/\( \text{Å}^3 \) | 849.9(3) |
| \( Z \)        | 2          |
| \( \rho_{\text{calc}} \) g/cm\(^3\) | 1.937 |
| \( \mu \) \( \text{mm}^{-1} \) | 5.997 |
| \( F(000) \)   | 490        |
| Radiation      | MoK\( \alpha \) (\( \lambda = 0.71073 \)) |
| 2\( \Theta \) range for data collection/\( \degree \) | 6.848–51.348 |
| Index ranges   | \(-13 \leq h \leq 13, -5 \leq k \leq 8, -13 \leq l \leq 14\) |
| Reflections collected | 3640 |
| Independent reflections | 1754 \([R_{\text{int}} = 0.0842, R_{\text{sigma}} = 0.1264]\) |
| Data/restraints/parameters | 1754/0/130 |
| Goodness-of-fit on \( R^2 \) | 1.017 |
| Final \( R \) indexes [I \( \geq 2\sigma(I)\)] | \( R_1 = 0.0751, wR_2 = 0.1581\) |
| Final \( R \) indexes [all data] | \( R_1 = 0.1214, wR_2 = 0.1902\) |
| Largest diff. peak/hole / e\( \text{Å}^{-3} \) | 1.12/–1.07 |
The coordination sphere of copper(II) consists of two bromides with an average Cu—Br bond length of 2.372 Å, a hydroxyl oxygen Cu—O of 1.987 Å, and Cu—N of 2.067 Å. The Cu(II) is a square planar with Br—Cu—Br close to 90° (97.03°). The furan and tertiary carbon in the adamantyl group and the amide arm (N and C) are aligned in a coplanar disposition. All bond lengths and angles are in agreement with those reported for similar copper(II) complexes [32–34]. The structure of crystal 1 is stabilized by the presence of hydrogen bonds between the bromine atoms and the L ligands (N—H···O, 2.665 Å). Figure 2 shows the packing of crystal 1 and Figure 3 describes the 1D-layer formed from these weak interactions in 1.

![Figure 1](image1.png)

**Figure 1.** Thermal ellipsoid drawing (50% probability level) of the asymmetric unit of 1.

The coordination sphere of copper(II) consists of two bromides with an average Cu—Br bond length of 2.372 Å, a hydroxyl oxygen Cu—O of 1.987 Å, and Cu—N of 2.067 Å. The Cu(II) is a square planar with Br—Cu—Br close to 90° (97.03°). The furan and tertiary carbon in the adamantyl group and the amide arm (N and C) are aligned in a coplanar disposition. All bond lengths and angles are in agreement with those reported for similar copper(II) complexes [32–34]. The structure of crystal 1 is stabilized by the presence of hydrogen bonds between the bromine atoms and the L ligands (N—H···O, 2.665 Å). Figure 2 shows the packing of 1 and Figure 3 describes the 1D-layer formed from these weak interactions in 1.

![Figure 2](image2.png)

**Figure 2.** Crystal packing along the c-axis of 1 shows the distorted octahedron around copper, the thermal ellipsoid drawing of 50%.
2.3. DFT Calculations

The stability of the square planar geometry in 1 was studied by DFT (6-31G(d)/B3LYP) calculations. Overall, we have designed two different models; one is built by enforcing the coordination around the copper atom to be square planar (SP), and the other as a distorted tetrahedron (DT). In the case of SP, the calculations lead to many negative vibration modes. This means unstable optimization with no global minima. The optimization of the monomer with a copper as DT was ended with no imaginary or negative modes. This means that the coordination of the monomer molecule would not be SP. This concludes that the in silico (gaseous) structure is not in agreement with the solid-state structure of 1 (Table 2) which is SP. A literature survey of LCuBr₂ complexes shows that many systems have been reported with distorted geometry and only a few possess square planar geometry [35–37]. Therefore, we optimized a dimer (Figures 4 and 5) to try mimicking the crystallographic structure. The results obtained indicated that there are no negative or imaginary modes and the copper coordination was almost square planar. These findings may indicate that the stability of such a type of coordination system might be due to the interactions (even very weak) in the solid state in 1. Figure 3 shows CH···Br intermolecular interaction in 1 with C···Br (3.776 Å) and C···H···Br (157.73°). Furthermore, Mulliken and ESP charge calculations show strong interactions between Br₁ (−0.4) from a monomer with the Cu₁ (+0.5) (Table 2) from others along b-axis which stabilize the square planar coordination (Figure 4). This could be due to the highly distorted octahedron. To confirm the possibility of having a distorted octahedron, we examined the frontier molecular orbitals and found that no molecular interactions were observed (Figure 5). Such findings unequivocally confirm that, in such complex, copper adopts a square planar geometry, which is rarely described in literature.
Table 2. Selected bond distances (Å) and bond angles (°) for 1. Experimental, optimized dimer and monomer structural data are presented.

|                  | Exp. dimer | Exp. monomer | Theo. dimer | Theo. monomer |
|------------------|------------|--------------|-------------|---------------|
| Cu1-Br1          | 2.376(2)   | 2.379        | 2.287       | 2.287         |
| Cu1-Br2          | 2.368(2)   | 2.323        | 2.298       | 2.298         |
| Cu1-O2           | 1.987(8)   | 2.094        | 2.036       | 2.036         |
| Cu1-N1           | 2.067(10)  | 2.094        | 2.061       | 2.061         |
| O2-C6            | 1.268(13)  | 1.241        | 1.243       | 1.243         |
| O1-C2            | 1.385(14)  | 1.382        | 1.382       | 1.382         |
| O1-C5            | 1.364(14)  | 1.362        | 1.361       | 1.361         |
| N2-N1            | 1.381(13)  | 1.376        | 1.372       | 1.372         |
| N2-C6            | 1.320(15)  | 1.357        | 1.364       | 1.364         |
| N1-C1            | 1.250(14)  | 1.295        | 1.294       | 1.294         |
| C1-C2            | 1.457(16)  | 1.433        | 1.432       | 1.432         |
| Cu1…Cu1          | 3.985      | 3.258        | -           | N2…O1         |
| Cu1…Br1          | 3.385      | 2.623        | -           | N1-Cu1-Br1    |
| Br2-Cu1-Br1      | 97.03(7)   | 93.50        | 109.09      | N1-Cu1-Br2    |
| O2-Cu1-Br1       | 173.9(2)   | 163.45       | 147.02      | Br1…N1N2C6O2  |
| O2-Cu1-Br2       | 89.0(2)    | 90.45        | 95.43       | Br2…N1N2C6O2  |
| O2-Cu1-N1        | 80.3(4)    | 77.04        | 77.93       | Cu1…N1N2C6O2  |

Figure 4. (a) ESP (electrostatic potential); and (b) Mulliken charge calculations at level 6-31G(d)/B3LYP for the dimer of 1.

Figure 5. Cont.
Figure 5. Presentation of the HOMO–LUMO in 1 obtained at 6-31G(d)/B3LYP of theory. (a) HOMO-1; (b) HOMO; (c) LUMO; (d) LUMO+1.

3. Materials and Methods

FTIR spectra were recorded with a Nicolet Impact 400 Fourier transform infrared Spectrophotometer (Madison, WI) in the 400–4000 cm⁻¹ region. KBr discs for solid samples were made by grinding 2 mg of the solid sample with about 0.2 g of KBr. A background spectrum was subtracted. Mass spectrometry experiments were performed in the negative mode on mass spectrometer (APEX-4 (7 Tesla), Bruker Daltonics, Bremen, Germany) equipped with an ESI source.

3.1. Synthesis of the Copper(II) Complex

The copper(II) complex of N’-(furan-2-ylmethylene) adamantane-1-carbohydrazide ligand (L) was prepared by the addition of a hot ethanol solution of the previously reported ligand (L) by our group [30,31] to an equimolar amount of copper(II) bromide [38]. The complex was precipitated immediately during stirring of the reaction mixture on a magnetic stirrer at room temperature. The precipitate was filtered, washed with cold ethanol, and dried at 60 °C in a vacuum oven for 2 hours to give the copper complex. Orange block-like crystals suitable for X-ray analysis were obtained: characteristics FTIR (KBr): ν = 1593 (s), 1526 (s), 525 (m). ESI-HRMS (m/z): 491.91148 calculated for C₁₆H₁₉Br₂CuN₂O₂ [M – H]⁻.

3.2. X-ray Diffraction Study

Single-crystal X-ray diffraction data were collected using an Oxford Diffraction XCalibur, equipped with (Mo) X-ray Source (λ = 0.71073 Å) at 291(2) K. Data collection, reduction, and cell refinement were performed using the software package CrysAlisPro [39]. Analytical absorption corrections were applied using spherical harmonics implemented in SCALE3 (ABSPACK) scaling algorithm. Crystal structure was solved by direct methods, using the program OLEX2, followed by Fourier synthesis, and refined on F² with SHELXL-97 [40]. Anisotropic least-squares refinement of non-H atoms was applied. All crystallographic plots were obtained using the CrystalMaker program [41]. A summary of the crystallographic data and structure refinement parameters is given in Table 1. Crystallographic data (excluding structure factors) for the structures in this paper have been deposited with the Cambridge Crystallographic Data Centre, CCDC, 12 Union Road, Cambridge CB21EZ, UK. Copies of the data can be obtained free of charge on quoting the depository number CCDC-1824898 (Fax: +44-1223-336-033; E-Mail: deposit@ccdc.cam.ac.uk, http://www.ccdc.cam.ac.uk). Selected bond lengths and angles are listed in Table 2.

3.3. Computational Details

B3LYP density functional theory (DFT) calculations were performed using the Gaussian 09 with its visual interference Gaussview 5 [42]. Due to the issues related to cost, 6-311G(d) basis sets were used.
for C, H, N, O, Br, and Cu. No symmetry constraint was imposed in the optimization. The vibration analyses were carried out to insure the non-existence of any negative/imaginary modes.

4. Conclusions

A new copper complex with N′-(furan-2-ylmethylene)adamantane-1-carbohydrazide is prepared and its crystal structure was determined. The coordination of the copper(II) is square planar which is rare. We carried out a DFT calculation and show that this coordination is not stable in (in silico) the gaseous phase. The stability of such coordination in the solid state may be attributed to the existence of weak intermolecular forces between Br and CH.

Acknowledgments: We wish to thank the Deanship of Academic Research (The University of Jordan) for financial support.

Author Contributions: M.A.K. and R.A.A. conceived and designed the experiments; A.M.J. performed the experiments; R.A.A. contributed reagents and materials, M.A.K. and M.A.A. analyzed the data and wrote the paper.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Rollas, S.; Gulerman, N.; Erdeniz, H. Synthesis and antimicrobial activity of some new hydrazones of 4-fluorobenzoic acid hydrazide and 3-acetyl-5-disubstituted-1, 3, 4-oxadiazolines. *Il Farmaco* 2002, 57, 171–174. [CrossRef]
2. Bedia, K.; Elçin, O.; Seda, U.; Fatma, K.; Nathaly, S.; Sevim, R.; Dimoglo, A. Synthesis and characterization of novel hydrazide–hydrazones and the study of their structure–antituberculosis activity. *Eur. J. Med. Chem.* 2006, 41, 1253–1261. [CrossRef] [PubMed]
3. Narang, R.; Narasimhan, B.; Sharma, S. A review on biological activities and chemical synthesis of hydrazide derivatives. *Curr. Med. Chem.* 2012, 19, 569–612. [CrossRef] [PubMed]
4. Vicini, P.; Zani, F.; Cozzini, P.; Doytchinova, I. Hydrazones of 1, 2-benzisothiazole hydrazides: synthesis, antimicrobial activity and QSAR investigations. *Eur. J. Med. Chem.* 2002, 37, 553–564. [CrossRef]
5. Ersan, S.; Nacak, S.; Berkem, R.; Ozden, T. Synthesis and antimicrobial activities of 2-[(alpha-methylbenzylidene)-hydrazino] benzoazoles. *Arzneim.-Forsch.* 1997, 47, 963–965.
6. Yıldır, I.; Percin, H.; Sahin, M.F.; Abbasoglu, U. Hydrazones of [2-Benzothiazolylthio] acetyl] hydrazine: Synthesis and Antimicrobial Activity. *Arch. Pharm.* 1995, 328, 547–549. [CrossRef]
7. Cesur, Z.; Büyüktimkin, S.; Büyüktimkin, N.; Derbentli, S. Synthesis and Antimicrobial Evaluation of Some Arylhydrazones of 4-[2-Methylimidazo [1, 2-a] pyridine-3-yl] azo] benzoic Acid Hydrazide. *Arch. Pharm.* 1990, 323, 141–144. [CrossRef]
8. Vittorio, F.; Ronnisville, G.; Marrazzo, A.; Blandini, G. Synthesis and antimicrobial evaluation of 4-phenyl-3-isouinolinolinyldihydrazones. *Il Farmaco* 1995, 50, 265–272. [PubMed]
9. Rasras, A.; Al-Tel, T.; Al-Aboudi, A.; Al-Qawasmeh, R. Synthesis and antimicrobial activity of cholic acid hydrazone analogues. *Eur. J. Med. Chem.* 2010, 45, 2307–2313. [CrossRef] [PubMed]
10. Vicini, P.; Incerti, M.; Doytchinova, I.A.; La Colla, P.; Busonera, B.; Loddo, R. Synthesis and antiproliferative activity of benzo [d] isothiazole hydrazones. *Eur. J. Med. Chem.* 2006, 41, 624–632. [CrossRef] [PubMed]
11. Rollas, S.; Kükущügüzel, S.G. Biological activities of hydrazone derivatives. *Molecules* 2007, 12, 1910. [CrossRef] [PubMed]
12. Al-Hazmi, G.A.; El-Asmy, A.A. Synthesis, spectroscopy and thermal analysis of copper (II) hydrazone complexes. *J. Coord. Chem.* 2009, 62, 337–345. [CrossRef]
13. Dawkins, A.T.; Gallager, L.R.; Togo, Y.; Hornick, R.B.; Harris, B.A. Studies on induced influenza in man: II. Double-blind study designed to assess the prophylactic efficacy of an analogue of amantadine hydrochloride. *J. Am. Med. Assoc.* 1968, 203, 1095–1099. [CrossRef]
14. Çalis, U.; Yarma, M.; Koksal, M.; Ozalp, M. Synthesis and antimicrobial activity evaluation of some new adamantane derivatives. *Arzneim.-Forsch.* 2002, 52, 778–781. [CrossRef]
15. Liu, J.; Obando, D.; Liao, V.; Lifa, T.; Codd, R. The many faces of the adamantyl group in drug design. *Eur. J. Med. Chem.* 2011, 46, 1949–1963. [CrossRef] [PubMed]
16. Kadi, A.A.; Al-Abdullah, E.S.; Shehata, I.A.; Habib, E.E.; Ibrahim, T.M.; El-Emam, A.A. Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1, 3, 4-thiadiazole derivatives. Eur. J. Med. Chem. 2010, 45, 5006–5011. [CrossRef] [PubMed]

17. Antoniadou-Vyza, E.; Avramidis, N.; Kourounakis, A.; Hadjipetrou, L. Anti-inflammatory properties of new adamantane derivatives. Design, synthesis, and biological evaluation. Arch. Pharm. Pharm. Med. Chem. 1998, 331, 72–78. [CrossRef]

18. Olson, S.; Aster, S.D.; Brown, K.; Carbin, L.; Graham, D.W.; Hermanowski-Vosatka, A.; LeGrand, C.B.; Mundt, S.S.; Robbins, M.A.; Schaeffer, J.M.; et al. Adamantyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett. 2005, 15, 4359–4362. [CrossRef] [PubMed]

19. Sondhi, S.; Dinodiaa, M.; Kumar, A. Synthesis, anti-inflammatory and analgesic activity evaluation of some amidine and hydrazone derivatives. Bioorg. Med. Chem. 2006, 14, 4657–4663. [CrossRef] [PubMed]

20. Fernández, J.M.; Acevedo-Arauz, E.; Cetina-Rosado, R.; Macías-Ruvalcaba, N.; Toscano, R.A. Electrochemical studies of copper (II) complexes derived from bulky Schiff bases. The crystal structure of bis[N-(1-adamantyl)-salicylaldiminato] copper (II). Trans. Met. Chem. 1999, 24, 18–24. [CrossRef]

21. Đorđević, M.; Jeremić, D.; Anđelković, K.; Pavlović, M.; Divjaković, V.; Brčesi, I. Cobalt (II) and cadmium (II) compounds with adamantane-1-sulfonic acid. J. Serb. Chem. Soc. 2012, 77, 1391–1399. [CrossRef]

22. Franco, J.; Olmstead, M.; Hammons, J. Bis[1-(1-adamantyliminomethyl)-2-naphtholato-κ2N, O] cobalt (II). Acta Crystallogr. Sect. E 2008, 64, m1223. [CrossRef] [PubMed]

23. Lee, Y.; Karlin, K.D. Model complexes for copper-containing enzymes. In Concepts and Models in Bioinorganic Chemistry; Kraatz, H.-B., Metzler-Nolte, N., Eds.; Wiley-VCH: Weinheim, Germany, 2006; pp. 363–396, ISBN 9783527313051.

24. Lippard, S.J.; Berg, J.M. Principles of Bioinorganic Chemistry; University Science Books: Mill Valley, CA, USA, 1994; pp. 1–6, ISBN 0935702725.

25. Da Silva, J.F.; Williams, R.J.P. The Biological Chemistry of the Elements: the Inorganic Chemistry of Life, 2nd ed.; Clarendon: Oxford, UK, 2001; pp. 7–26, ISBN 9780198508489.

26. Teyssot, M.-L.; Jarrousse, A.-S.; Chevry, A.; De Haze, A.; Beaudoin, C.; Manin, M.; Nolan, S.P.; Diez-Gonzalez, S.; Morel, L.; Gautier, A. Toxicity of Copper (I)–NHC Complexes Against Human Tumor Cells: Induction of Cell Cycle Arrest, Apoptosis, and DNA Cleavage. Chem. Eur. J. 2009, 15, 314–318. [CrossRef] [PubMed]

27. McGivern, T.J.P.; Afsharpour, S.; Marmion, C.J. Copper complexes as artificial DNA metallonucleases: From Sigman’s reagent to next generation anti-cancer agent? Inorg. Chim. Acta 2017, 472, 12–39. [CrossRef]

28. Santini, C.; Pellei, M.; Gandin, V.; Porchia, M.; Tisato, F.; Marzano, C. Advances in Copper Complexes as Anticancer Agents. Chem. Rev. 2014, 114, 815–862. [CrossRef] [PubMed]

29. Akitsu, T. A Metal Complex Incorporating Some Drug Molecules as Ligands. EC Pharmacol. Toxicol. 2017, ECO.01, 16–18.

30. Al-Qawasmeh, R.A.; Salameh, B.; Alrazim, R.; Aldamen, M.; Voelter, W. Microwave Assisted Synthesis of New Adamantyltriazine Derivatives. Lett. Org. Chem. 2014, 11, 513–518. [CrossRef]

31. Al-Aboudi, A.; Al-Qawasmeh, R.A.; Shahwan, A.; Mahmood, U.; Khalid, A.; Ul-Haq, Z. In-silico identification of the binding mode of synthesized adamantyl derivatives inside cholinesterase enzymes. Acta Pharmacol. Sin. 2015, 36, 879–886. [CrossRef] [PubMed]

32. Zhou, X.-Q.; Li, Y.; Zhang, D.-Y.; Nie, Y.; Li, Z.-J.; Gu, W.; Liu, X.; Tian, J.-L.; Yan, S.-P. Copper complexes based on chiral Schiff-base ligands: DNA/BSA binding ability, DNA cleavage activity, cytotoxicity and mechanism of apoptosis. Eur. J. Med. Chem. 2016, 114, 244–256. [CrossRef] [PubMed]

33. Koval’chukova, O.V.; Zavodnik, V.E.; Shестаков, А.Е.; Strashnovaa, S.B.; Zaitseva, B.E. Experimental and Theoretical Investigation of the Structure and Spectral Characteristics of Bis(4-aza-9-fluorenone) dibromocopper(II). Russ. J. Inorg. Chem. 2010, 55, 195–200. [CrossRef]

34. Vela, S.; Deumal, M.; Turnbull, M.M.; Novoa, J.J. A theoretical analysis of the magnetic properties of the low-dimensional copper(II)X2(2-X-3-methylpyridine)2(X = Cl and Br) complexes. Theor. Chem. Acc. 2013, 132, 1331. [CrossRef]
35. Posada, N.B.; Guimarães, M.A.; Padilha, D.S.; Resende, J.A.; Faria, R.B.; Lanzmater, M.; Amado, R.S.; Scarpellini, M. Influence of the secondary coordination sphere on the physical properties of mononuclear copper (II) complexes and their catalytic activity on the oxidation of 3,5-di-tert-butylcatechol. *Polyhedron* **2018**, *141*, 30–36. [CrossRef]

36. Piri, Z.; Moradi-Shoeili, Z.; Assoud, A. New copper (II) complex with bioactive 2-acetylpipridine-4N-p-chlorophenylthiosemicarbazone ligand: Synthesis, X-ray structure, and evaluation of antioxidant and antibacterial activity. *Inorg. Chem. Commun.* **2017**, *84*, 122–126. [CrossRef]

37. Thomas, F.; Kochem, A.; Molloy, J.K.; Gellon, G.; Leconte, N.; Philouze, C.; Jarjayes, O.; Berthiol, F. A structurally characterized Cu (III) complex supported by a bis (anilido) ligand and its oxidative catalytic activity. *Chem. Eur. J.* **2017**, *23*, 13929–13940. [CrossRef]

38. Singh, K.; Kumar, Y.; Parvesh, P.; Sharma, C.; Aneja, K. Metal-Based Biologically Active Compounds: Synthesis, Spectral, and Antimicrobial Studies of Cobalt, Nickel, Copper, and Zinc Complexes of Triazole-Derived Schiff Bases. *Bioinorg. Chem. Appl.* **2011**, *2011*, 901716–901726. [CrossRef] [PubMed]

39. *CrysAlis Software System*; Version 1.171; Oxford Diffraction Ltd.: Oxford, England, 2002.

40. *SHELXL*, Version 97; Program for X-ray Crystal Structure Refinement; University of Göttingen: Göttingen, Germany, 1997.

41. *Images generated using CrystalMaker(R)*, version 9; A crystal and molecular structures program for Mac and Windows (www.crystalmaker.com); CrystalMaker Software Ltd.: Oxford, UK, 2015.

42. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Zakrzewski, V.G.; Montgomery, J.A., Jr.; Stratmann, R.E.; Burant, J.C.; et al. *Gaussian 03*; Revision 05; Gaussian Inc.: Pittsburgh, PA, USA, 2003.

**Sample Availability:** Samples of the compound 1 is available from the authors.

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).